Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity

Go back to Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1288.30 +6.39 (0.50%)
Previous Close $1281.91    52 Week High $88.16 
Open $1268.55    52 Week Low $67.88 
Day High $1299.43    P/E 298.22 
Day Low $1260.34    EPS $4.32 
Volume 2,056,521